Sclerema Neonatorum 

  • Author: Amy J Theos, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Oct 11, 2010
 

Background

The classic description of sclerema neonatorum (SN) is credited to Underwood, who described it in 1784 and appropriately termed it "skinbound disease." In 1817, Alibert introduced the term sclerema, derived from the Greek word skleros, meaning hard. Sclerema neonatorum is a disorder of the subcutaneous fat in debilitated neonates and is considered best as a sign of a potentially fatal underlying disease process and not a specific disease entity.[1] A thorough review of the nomenclature, clinical findings, histological features, differential diagnosis, and management of sclerema neonatorum was published in 2008.[2]

The Medscape Pediatric Dermatology Resource Center may be of interest.

Next

Pathophysiology

In an infant, fat has a higher saturated-to-unsaturated fatty acid ratio compared to adult fat and thus, a higher melting point. Prematurity, hypothermia, shock, and metabolic abnormalities have been postulated to further increase this ratio, possibly as a result of enzymatic alteration allowing precipitation of fatty acid crystals within the lipocytes. This condition has been suggested to result in the dramatic clinical findings in affected skin. X-ray diffraction techniques have confirmed that infants with sclerema neonatorum have an increase in saturated fats and that the crystals within the fat cells are composed of triglycerides.[3]

Previous
Next

Epidemiology

Frequency

United States

The exact incidence of sclerema neonatorum is unknown. All studies describe sclerema neonatorum as extremely rare. The number of reported cases in recent years has declined, probably as a result of better neonatal care.

International

A 10% incidence of sclerema neonatorum was documented in preterm neonates admitted to a hospital in Bangladesh. Risk factors for developing sclerema neonatorum in these infants included poor feeding, jaundice, and bacteremia.[4]

Mortality/Morbidity

Because sclerema neonatorum invariably is associated with serious underlying disease, the mortality rate is high. In different series, the reported mortality rates range from 67-88%, with death occurring hours to days after onset. If the underlying disease is treated successfully, the skin softens and returns to normal.

Race

No racial predilection has been reported.

Sex

Sclerema neonatorum shows a slight male predominance, with an estimated male-to-female ratio of 1.5:1.[5]

Age

Sclerema neonatorum is a disease confined to the newborn period. Sclerema neonatorum can present at birth, but onset within the first week of life is more common. The oldest reported infant presented with Pseudomonas septicemia at age 106 days.

Previous
 
 
Contributor Information and Disclosures
Author

Amy J Theos, MD  Director of Pediatric Dermatology, Associate Professor, Department of Dermatology, University of Alabama at Birmingham

Amy J Theos, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Society for Pediatric Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

Craig A Elmets, MD  Professor and Chair, Department of Dermatology, Director, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Craig A Elmets, MD is a member of the following medical societies: American Academy of Dermatology, American Association of Immunologists, American College of Physicians, American Federation for Medical Research, and Society for Investigative Dermatology

Disclosure: Palomar Medical Technologies Stock None; Amgen Consulting fee Review panel membership; Astellas Consulting fee Review panel membership; Massachusetts Medical Society Salary Employment; Abbott Laboratories Grant/research funds Independent contractor

Specialty Editor Board

Daniel Mark Siegel, MD, MS  Director, Procedural Dermatology Fellowship Program, Clinical Professor of Dermatology, Department of Dermatology, State University of New York Downstate

Daniel Mark Siegel, MD, MS is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American College of Physician Executives, American Society for Dermatologic Surgery, American Society for MOHS Surgery, and International Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Richard P Vinson, MD  Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Van Perry, MD  Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas Health Science Center

Van Perry, MD is a member of the following medical societies: American Academy of Dermatology and American Society for Laser Medicine and Surgery

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Warwick WJ, Ruttenberg HD, Quie PG. Sclerema neonatorum--a sign, not a disease. JAMA. Jun 1 1963;184:680-3. [Medline].

  2. Zeb A, Darmstadt GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol. Jul 2008;28(7):453-60. [Medline].

  3. Kellum RE, Ray TL, Brown GR. Sclerema neonatorum. Report of a case and analysis of subcutaneous and epidermal-dermal lipids by chromatographic methods. Arch Dermatol. Apr 1968;97(4):372-80. [Medline].

  4. Zeb A, Rosenberg RE, Ahmed NU, Saha SK, Chowdhury A, Ahmed S, et al. Risk factors for sclerema neonatorum in preterm neonates in Bangladesh. Pediatr Infect Dis J. May 2009;28(5):435-8. [Medline].

  5. Bwibo NO, Anderson BT. Sclerema neonatorum (a study of 16 cases in the special care unit, Mulago Hospital, Kampala). East Afr Med J. Jan 1970;47(1):50-5. [Medline].

  6. Milunsky A, Levin SE. Sclerema neonatorum: a clinical study of 79 cases. S Afr Med J. Jul 2 1966;40(27):638-41. [Medline].

  7. Fretzin DF, Arias AM. Sclerema neonatorum and subcutaneous fat necrosis of the newborn. Pediatr Dermatol. Aug 1987;4(2):112-22. [Medline].

  8. Battin M, Harding J, Gunn A. Sclerema Neonatorum following hypothermia. J Paediatr Child Health. Oct 2002;38(5):533-4. [Medline].

  9. Navarini-Meury S, Schneider J, Bührer C. Sclerema neonatorum after therapeutic whole-body hypothermia. Arch Dis Child Fetal Neonatal Ed. Jul 2007;92(4):F307. [Medline].

  10. Torrelo A, Hernández A. Panniculitis in children. Dermatol Clin. Oct 2008;26(4):491-500. [Medline].

  11. Sadana S, Mathur NB, Thakur A. Exchange transfusion in septic neonates with sclerema: effect on immunoglobulin and complement levels. Indian Pediatr. Jan 1997;34(1):20-5. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.